ALAMEDA

The EU-funded ALAMEDA project aims to provide new opportunities for improved personalized healthcare and prevention that have been enabled by the recent advances in the design and development of Innovative health risk prediction and intervention tools. ALAMEDA’s vision is to research and prototype the next generation of personalized AI healthcare support systems for people with brain diseases and disorders, specifically focusing on the needs of patients with Parkinson’s, Multiple Sclerosis and Stroke (PMSS). The project’s innovations will take advantage of new machine learning models, built upon lifestyle retrospective data as well as new streams of patient data that involve the monitoring of everyday activities, such as sleep behaviour and emotional status.

The success of such applications will provide clinicians with the opportunity to modify interventions based on personalized data recordings, that could include both pharmacological and non-pharmacological therapeutic options, such as exercise regimens.

The Alameda consortium comprises 15 partners from 8 different European countries.

Consortium

INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS (ICCS) Greece
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON (NKUA) Greece
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS (CERTH) Greece
ENORA INNOVATION ETAIREIA PSIFIAKON TEXNOLOGION KAI ERGON KAINOTOMIAS IDIOTIKI KEFALAIOUXIKI ETAIREIA (ENO) Greece
WELLICS LTD (WCS) United Kingdom
EY ADVISORY SPA (EY) Italy
FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS (FISM) Italy
PLURIBUS ONE SRL (PLU) Italy
UNIVERSITATEA POLITEHNICA DIN BUCURESTI (UPB) Romania
SPITALUL UNIVERSITAR DE URGENTA BUCURESTI (SUUB) Romania
NORGES TEKNISK-NATURVITENSKAPELIGE Universitet (NTNU) Norway
UNISYSTEMS LUXEMBURG SARL (UNISYS) Luxamburg
WISE ANGLE CONSULTING SL (WISE) Spain
CATALINK LIMITED (CTL) Cyprus
UNIVERSITY OF NICOSIA (UNIC) Cyprus